Regeneron Pharmaceuticals, Inc.
ANTI-IL36R ANTIBODIES
Last updated:
Abstract:
The present invention provides antibodies and antigen-binding fragments (e.g., human antibodies) that bind specifically to human Interleukin-36 receptor (IL36R). Methods for treating or preventing diseases mediated by IL36R (e.g., skin or colon inflammatory conditions such as palmo-plantar pustular psoriasis, palmoplantar pustulosis, generalized pustular psoriasis, ulcerative colitis or IBD) using the antibodies and fragments are also provided along with methods of making the antibodies and fragments.
Status:
Application
Type:
Utility
Filling date:
1 Feb 2022
Issue date:
26 May 2022